ArticleTranslational lung cancer research2019
Sleeve lobectomy compared with pneumonectomy for operable centrally located non-small cell lung cancer: a meta-analysis.
Article in Translational lung cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- The expert consensus document on minimally invasive upper lobectomy for lung cancer in China.Journal of thoracic disease · 2026Review
- Perioperative Systemic Therapies in Resectable Non-Small Cell Lung Cancer: Opportunities and Challenges.Journal of clinical medicine · 2026Review
- Surgical strategy after neoadjuvant immunochemotherapy for central-type NSCLC: restaging-guided versus pre-treatment-guided decision-making.Translational lung cancer research · 2026Article
- Complex uniportal robotic-assisted sleeve resections under spontaneous ventilation and with double lumen intubation: a case series and a narrative review of the literature.Translational lung cancer research · 2025Review
- Analysis of the safety and feasibility of sleeve resection under UniVATS after neoadjuvant chemotherapy combined with immunotherapy for locally advanced central-type non-small cell lung cancer.World journal of surgical oncology · 2025Article
- NSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives.Journal of clinical medicine · 2025Review
- The impact of neoadjuvant therapy on postoperative outcomes following sleeve lobectomy for locally advanced non-small cell lung cancer: a call for future investigation.Journal of thoracic disease · 2024Article
- Article
- Safety and Efficacy of Neoadjuvant Chemoimmunotherapy versus Chemotherapy for Non-Small Cell Lung Cancer Undergoing Sleeve Resection.Cancer management and research · 2024Review
- Carinal Resection and Extended Sleeve Lobectomy After Right Upper Sleeve Lobectomy: 1 Step Beyond.Annals of thoracic surgery short reports · 2023Article
- Surgical training in extended sleeve lobectomy with fresh-frozen human cadavers: a case report.General thoracic and cardiovascular surgery cases · 2023Article
- Comparison of efficacy and safety of hybrid video-assisted thoracoscopic surgeryJournal of thoracic disease · 2022Article
- Feasibility and safety of pedicled autologous bronchial flap reconstruction airway instead of sleeve lobectomy in partial lung cancer surgery.Translational lung cancer research · 2022Article
- The long-term oncologic outcomes of robot-assisted bronchial single sleeve lobectomy for 104 consecutive patients with centrally located non-small cell lung cancer.Translational lung cancer research · 2022Article
- [Experience of Thoracotomy and Robot-assisted Bronchial Sleeve Resection after Neoadjuvant Chemoimmunotherapy for Local Advanced Central Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Article
- Techniques and outcomes of bronchoplastic and sleeve resection: an 8-year single-center experience.Translational lung cancer research · 2021Article
- Is sleeve lobectomy safe after induction therapy?-a systematic review and meta-analysis.Journal of thoracic disease · 2021Article
- A meta-analysis of minimally invasive surgery versus thoracotomy for centrally located non-small cell lung cancer.Journal of thoracic disease · 2021Article
- Sleeve lobectomy and pneumonectomy: can they really be properly compared?Translational lung cancer research · 2020Article
- Surgical outcomes of segmental bronchial sleeve resection in central non-small cell lung cancer.Thoracic cancer · 2020Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this meta-analysis was to evaluate evidence comparing sleeve lobectomy (SL) and pneumonectomy (PN) in the treatment of non-small cell lung cancer (NSCLC).
methodsThe English literature search was undertaken in January 2018 and included studies dating back to 1996. Comparative studies were identified, evaluating survival, local recurrence, and distant recurrence rates, operative mortality, 30-day mortality, as well as complications. A pooled odds ratio (OR) and 95% confidence intervals (95% CI) were calculated with either the random or fixed-effect model.
resultsA total of 27 studies were identified, with publication dates between 1996 and 2018. These 27 studies included a total of 14,194 patients: 4,145 treated with SL and 10,049 treated with PN. The overall survival was significantly higher in the SL group compared to the PN one at 1, 3, 5 years. In patients with N0 and N1 disease, 5-year survival rates following SL exceeded those following PN. There was no statistically significant difference in the 3-, 5-year overall survival of N2 patients, according to the extent of surgery. The PN group had a higher rate of operative mortality, 30-day mortality and distant recurrence incidence. However, no statistical difference in complications and local recurrence between SL and PN were observed.
conclusionsSL is an effective treatment option for hilar NSCLC with improved long-term survival compared to PN, with no increase of recurrence rate or postoperative complications. Furthermore, N2 disease is an important factor related to survival, and lymph node downstaging is a favorable prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.